TRADEMARK ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE:

CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES
TRADEMARKS (EXCLUSIVELY LICENSED TRADEMARKS)

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Endo Pharmaceuticals Inc.		11/30/2010	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	JPMorgan Chase Bank, N.A., as Administrative Agent
Street Address:	10 South Dearborn
City:	Chicago
State/Country:	ILLINOIS
Postal Code:	60603
Entity Type:	National Banking Assocation: UNITED STATES

PROPERTY NUMBERS Total: 10

Property Type	Number	Word Mark
Registration Number:	1597110	LIDODERM
Registration Number:	2870973	LIDODERM
Registration Number:	2853072	LIDODERM
Registration Number:	1821958	TAKON
Registration Number:	3544556	
Registration Number:	0960282	VOLTAREN
Registration Number:	2828476	FROVA
Registration Number:	3281355	FROVA
Registration Number:	2139652	ORTHOTRIPSY
Registration Number:	2154207	OSSATRON

CORRESPONDENCE DATA

Fax Number: (214)981-3400

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 214-981-3483 Email: dclark@sidley.com Correspondent Name: Dusan Clark, Esq. Address Line 1: Sidley Austin LLP 717 N. Harwood St., Suite 3400 Address Line 2: Address Line 4: Dallas, TEXAS 75201 ATTORNEY DOCKET NUMBER: 36084-36730 NAME OF SUBMITTER: **Dusan Clark** /Dusan Clark/ Signature: Date: 12/01/2010 **Total Attachments: 5** source=Ex. Lic. IP CGSI TM#page1.tif source=Ex. Lic. IP CGSI TM#page2.tif source=Ex. Lic. IP CGSI TM#page3.tif source=Ex. Lic. IP CGSI TM#page4.tif source=Ex. Lic. IP CGSI TM#page5.tif

CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS

THIS CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Confirmatory Grant") is made effective as of November 30, 2010 by and from ENDO PHARMACEUTICALS INC., a Delaware corporation (the "Grantor"), to and in favor of JPMORGAN CHASE BANK, N.A., for itself and as Administrative Agent for the Secured Parties (as defined in the Credit Agreement referenced below) (in such capacities, the "Grantee").

WHEREAS, Endo Pharmaceuticals Holdings Inc. (the "Borrower"), the Lenders and the Grantee have entered into a Credit Agreement dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement").

WHEREAS, the Grantor, along with certain other Subsidiaries of the Borrower, has guaranteed the repayment of the Secured Obligations pursuant to a Guaranty dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Guaranty").

WHEREAS, the Borrower, the Grantor and certain Subsidiaries of the Borrower have entered into a Pledge and Security Agreement dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement").

WHEREAS, the Grantor is the exclusive licensee of the trademarks listed on <u>Exhibit A</u> attached hereto (the "<u>Trademarks</u>"), which Trademarks are pending or registered with the United States Patent and Trademark Office.

WHEREAS, this Confirmatory Grant has been executed in conjunction with the security interest granted under the Security Agreement to the Grantee for the benefit of the Secured Parties. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1) <u>Definitions</u>. All capitalized terms not defined herein shall have the respective meaning given to them in the Credit Agreement.

2) <u>The Security Interest.</u>

(a) This Confirmatory Grant is made to secure the satisfactory performance and payment of (i) all the Secured Obligations and (ii) all of the obligations and liabilities of the Subsidiary Guarantors under the Guaranty. Upon the payment in full of all Secured Obligations (other than Unliquidated Obligations), the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the Grantor all reasonably requested instruments in writing releasing the security interest in the Trademarks acquired under the Security Agreement and this Confirmatory Grant.

- (b) The Grantor hereby pledges and grants to the Grantee, on behalf of and for the benefit of the Secured Parties, a security interest in all of the Grantor's right, title and interest in and to the trademark registrations and trademark applications under and to the extent set forth in and permitted by the exclusive license to Grantor of such trademark registrations and trademark applications.
- 3) <u>Governing Law</u>. THIS CONFIRMATORY GRANT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant effective as of the date first written above.

ENDO PHARMACEUTICALS INC.

Name: Alan G. Levin

Title: Executive Vice President and Chief Financial

Officer

Signature Page for Grant of Security Interest in United States Trademarks

CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES TRADEMARKS Exhibit A - SCHEDULE OF LICENSED TRADEMARKS

Exhibit A

Licensed Marks

Trademark	Country	App. No.	App.Date	Reg. No.	Reg.Date Owner	Owner
LIDODERM	United States	73/790,107	3/30/1989	1,597,110	5/22/1990	Hind Health Care
LIDODERM	United States	76/487,897	2/6/2003	2,870,973	8/10/2004	Hind Health Care
LIDODERM & Design	United States	76/522,165	6/12/2003	2,853,072	6/15/2004	Hind Health Care, Inc.
TAKON	United States	74339115	12/11/1992	1821958	2/15/1994	Hind Health Care, Inc.
JOY OF MOVEMENT	United States	77/053,235	11/29/2006			Novartis AG
Design Only	United States	77/258,978	8/20/2007	3,544,556	12/9/2008	Novartis AG
VOLTAREN	United States	72/422,688	4/28/1972	0,960,282	6/5/1973	Novartis Corporation
FROVA	United States	78/017,693	7/20/2000	2,828,476	3/30/2004	Vernalis Development Limited
FROVA & Design	United States	76/668,676	11/7/2006	3,281,355	8/21/2007	Vernalis Development Limited
ORTHOTRIPSY	United States	75/123,779	6/21/1996	2,139,652	2/24/1998	Sanuwave, Inc.
OSSATRON	United States	75/123,776	6/21/1996	2,154,207	4/28/1998	Sanuwave, Inc.

TRADEMARK REEL: 004423 FRAME: 0382

RECORDED: 12/01/2010